As of 10:30 AM on the 30th, Celltrion is trading at 248,000 KRW, down 1.98% from the previous day. The trading volume is 265,378 shares, which is about 27.21% of the previous day's volume. Celltrion is known as a protein and biopharmaceutical manufacturing company.
On October 27, researcher Lee Dalmi from SK Securities stated, "The company's COVID-19 treatment drug is currently in phases 2 and 3 of clinical trials. They aim to announce phase 2 results by the end of 2020, and if the results are positive, they plan to apply for emergency use authorization. The drug could be launched as early as the beginning of 2021. There may be some burden regarding clinical trial costs, but it is expected not to exceed the usual annual clinical trial cost level (30% of sales), so it should not be a significant burden. At this point, it is considered a buying opportunity at a low price." He set Celltrion's target price at 370,000 KRW.
Over the past five days, individual investors have net purchased 193,703 shares of Celltrion, while foreign investors and institutions have net sold 116,360 shares and 81,661 shares, respectively.
※Source: AI Investment Assistant AI Rassiro
※ This article was generated in real-time by an automatic article generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
